J6M0-mcMMAF (GSK2857916) binds more strongly to MM target cells and has no adverse negative impacts on BCMA-negative cells (NK, monocytes, PBMCs, or BMSCs) [17]. Here, TNFRSF17 is linked to Miyoshi myopathy.